Rallybio Corp (RLYB) 10-K Summary: Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Rallybio Corp is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. The reporting period covers the fiscal year ended December 31, 2025. The company's lead program, RLYB116 (a C5 inhibitor), completed a confirmatory Phase 1 trial in 2025. In April 2025, the company discontinued its RLYB212 program due to insufficient pharmacokinetic data. On March 1, 2026 (subsequent to the reporting period), Rallybio entered into a definitive Merger Agreement with Candid Therapeutics, Inc., a clinical-stage biotech focused on T-cell engagers.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $0.9 million | $0.6 million |
| Net Loss | $(9.0) million | $(57.8) million |
| Operating Expenses | $33.9 million | $61.1 million |
| Research & Development | $19.6 million | $41.5 million |
| General & Administrative | $14.3 million | $19.6 million |
| Cash, Cash Equivalents & Marketable Securities | $54.7 million | $65.5 million |
| Accumulated Deficit | $(302.0) million | $(293.0) million |
| Net Cash Used in Operating Activities | $(29.8) million | $(49.3) million |
Note: The 2025 net loss includes a $23.0 million gain from the sale of a joint venture interest (JV Sale) to Recursion Pharmaceuticals. Without this gain, the operating loss would have been significantly higher.
Material Changes vs. Prior Period
- Revenue Increase: Collaboration and license revenue increased by $0.2 million, driven by the Johnson & Johnson (J&J) collaboration agreement and revenue recognition related to the J&J securities purchase agreement.
- Expense Reduction: Total operating expenses decreased by $27.2 million. R&D expenses dropped $21.9 million, primarily due to the discontinuation of the RLYB212 program ($15.0 million reduction) and reduced headcount. G&A expenses decreased $5.3 million due to lower personnel costs and professional fees.
- Asset Sale: In July 2025, the company sold its interest in REV102 (an ENPP1 inhibitor) to Recursion for $20.0 million in cash and contingent consideration, resulting in a $22.4 million gain recognized in 2025.
- Restructuring: In May 2025, the company reduced its workforce by approximately 40%, incurring $1.7 million in restructuring charges.
Guidance, Outlook, and Risks
Merger with Candid Therapeutics: The company is pursuing a merger with Candid Therapeutics. Under the agreement, pre-merger Rallybio shareholders are expected to own approximately 3.65% of the combined company. Rallybio shareholders will receive Contingent Value Rights (CVRs) entitling them to proceeds from the disposition of Rallybio's legacy assets (including RLYB116) and future payments from Recursion. The merger is subject to regulatory approval and stockholder votes.
Liquidity: As of December 31, 2025, the company held $54.7 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least 12 months beyond the filing date, assuming the merger is completed in 2026. If the merger fails, the company will require significant additional capital.
Risks and Contingencies:
- Merger Failure: Failure to complete the merger could result in a termination fee of $1.425 million and leave the company with limited resources to continue operations.
- CVRs: The value of CVRs is contingent on the successful monetization of legacy assets; they may expire valueless if no disposition agreements are reached.
- Regulatory: The company faces standard biotech risks regarding clinical trial outcomes and regulatory approval for RLYB116.
- Listing Compliance: The company recently executed a 1-for-8 reverse stock split to regain compliance with Nasdaq listing requirements regarding minimum bid price.
Key Facts for Investor Verification
- Merger Terms: Verify the final exchange ratio and the specific conditions for the CVR payments, as current projections assume a $47.5 million valuation for Rallybio and $37.5 million in net cash at closing.
- RLYB116 Progress: Confirm the timeline for the next clinical trials for RLYB116, as the company is winding down general operations to focus on advancing this asset for potential disposition.
- Cash Runway: Monitor cash burn rates closely if the merger is delayed or terminated, as the company has no commercial revenue and relies on financing or asset sales.
- Recursion Payments: Track the status of the $5.0 million milestone payment from Recursion, which is contingent on the initiation of dosing in a Phase 1 clinical study for REV102.
- Stock Dilution: Note that existing shareholders will be significantly diluted (to ~3.65%) in the combined entity, with the majority of value potentially residing in the CVRs.